Lytix Biopharma Wins Shareholder Backing for NOK 30m Offering and Conversion to Public Company
I'm PortAI, I can summarize articles.
Lytix Biopharma AS has received shareholder approval for a NOK 30 million offering and will convert to a public limited liability company, changing its name to Lytix Biopharma ASA. The extraordinary general meeting also approved amendments to the articles of association, elected Darlene Deptula-Hicks to the board until 2027, and set the subscription period for the new share offering from January 27 to February 10, 2026. These actions aim to strengthen Lytix's capital base and governance as it advances its oncology pipeline.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments